| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_601ff9a87c8420b97f345cbc61587d83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c951ab2664cafdb7e987bd812fdea427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b73c0e74de8e59789728a49f9f56ff3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c48e6a6560662d9ca60add45fecea0a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8125 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-00 |
| filingDate |
2010-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_419fd348ce8ab372601050e8bd9c0927
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_670f2b2bce9b3e871faa079123bae2b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72b708999e25bd4e3c227bd7ded7dda1 |
| publicationDate |
2012-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012094356-A1 |
| titleOfInvention |
In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasng in vivo half-life using same |
| abstract |
The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018071528-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9902753-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015518882-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10730929-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10723785-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11492390-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11046752-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9789165-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9775904-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9694053-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9750788-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9745360-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9771406-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9758561-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9751926-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9670261-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10806797-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9982029-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10253079-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9932381-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10400029-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10758592-B2 |
| priorityDate |
2009-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |